FDA Clears a Much Faster, Subcutaneous Formulation of Keytruda a Practical Shift in Cancer Care0

• HEALTH, SCIENCE-TECH, WORLD
• September 22, 2025

n a development that could meaningfully alter patient experience and clinic workflows for a broad set of oncology patients, the U.S. Food and Drug Administration on September 19 approved a subcutaneous (under-the-skin) formulation of pembrolizumab branded Keytruda Qlex that reduces administration time from the typical half-hour intravenous infusion to a one-to-two-minute injection depending on dose;